« Return to News | Drug Sponsors

Promedior opens new office and labs in Lexington, Mass.

Monday, December 17, 2012 03:34 PM

Promedior, a clinical stage biotechnology company focused on fibrosis, is opening its new office and laboratory space at 101 Hartwell Avenue, Lexington, Mass.

Consolidating all of its operations, the new facility will serve as the company's headquarters and completes the corporate move from the suburbs of Philadelphia, Penn. Promedior's new facility includes state-of-the-art laboratories to support product development and commercialization of the company's novel pentraxin-2 therapeutics to treat fibrosis, including a number of rare diseases such as idiopathic pulmonary fibrosis (IPF) and myelofibrosis.

"Our new facility in Massachusetts positions us to expand our capabilities and accelerate our products forward, as we attract a highly-skilled team to develop and commercialize breakthrough therapeutics to treat fibrotic diseases for which there are few, if any, treatment options for patients," said Suzanne L. Bruhn, Ph.D., president and CEO of Promedior.

Promedior's pipeline of therapeutics for fibrosis includes drug development programs targeted at rare diseases. The company joins more than 50 biotechnology companies located in New England that have commercial drugs or drug development programs for rare diseases.

Promedior's growth plans in 2013 include advancing a clinical program in myelofibrosis and moving forward with a program in ocular disease.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.